Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
June 8, 2020

ASCO 2020: Overall survival benefit from secondary cytoreductive surgery, and results from SOLO-2 and FORWARD II for recurrent ovarian cancer

By Victoria Smith

ASCO 2020 Virtual Scientific Program, which took place 29 May – 2 June, reported results from clinical trials, highlighting a number of key developments in ovarian cancer treatment, which collectively show the value of innovative therapies in various patient subgroups, offering guidance to the treatment of recurrent ovarian cancer.

One of the highly anticipated presentations in ASCO 2020 was results from DESKTOP III/ENGOT-ov20 trial (abstract #6000), which demonstrated a clear survival benefit from secondary cytoreductive surgery in recurrent ovarian cancer. Read more here.

Related Companies

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU